BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

BioRestorative Therapies' drug candidate BRTX-100 has successfully passed a safety test and is now moving forward with its Phase 2 clinical trial. The trial focuses on chronic lumbar disc disease, and the independent review board overseeing the trial has unanimously recommended its continuation without any changes to the protocol. &nbsp This recommendation from the Data Safety Monitoring Board (..